TransMedics
TMDX
85.25
-8.77
-9.33%
TransMedics
US · TMDX
#2536 by market cap
Listed 2019
85.25
-8.77
-9.33%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $124Market Newswire · 2026/6/30
-
Rating change
Needham Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $106Market Newswire · 2026/9/22
-
Rating change
Needham Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $106Market Newswire · 2026/8/3
-
Rating change
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $95 to $106Market Newswire · 2026/9/11
-
Rating change
Evercore Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90Market Newswire · 2026/7/6
-
Rating change
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $95 to $122Market Newswire · 2026/8/5
-
Rating change
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $120Market Newswire · 2026/7/7
-
Barclays Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/11/9
-
Rating change
TransMedics (TMDX): Buy Rating Backed by Accelerating U.S. Organ Transplant Volumes and Expanding OCS UtilizationTipRanks · 2026/8/3
-
Rating change
William Blair Maintains TransMedics(TMDX.US) With Buy RatingMarket Newswire · 2026/10/2
-
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/11/6
-
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $70 to $120Market Newswire · 2026/11/7
-
Rating change
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Raises Target Price to $100Market Newswire · 2026/9/12
-
Rating change
CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $95Market Newswire · 2026/8/13
-
Rating change
Oppenheimer Maintains TransMedics(TMDX.US) With Hold RatingMarket Newswire · 2026/8/24
-
CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $94Market Newswire · 2026/10/13
-
Rating change
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/7/22
-
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/11/3
-
Rating change
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90Market Newswire · 2026/9/2
-
Rating change
Barclays Initiates TransMedics(TMDX.US) With Buy Rating, Announces Target Price $120Market Newswire · 2026/10/7
-
Rating change
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)TipRanks · 2026/6/26
-
Rating change
Stifel Maintains TransMedics(TMDX.US) With Hold Rating, Maintains Target Price $80Market Newswire · 2026/6/26
-
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $120Market Newswire · 2026/10/2
-
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $100Market Newswire · 2026/10/5
-
GUIDANCE: (TMDX) TransMedics Expects Full Year 2026 Revenue Range $737M - $757M, Vs. FactSet Est of $743.1MMT Newswires · 2026/9/11
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
TransMedics discussion 0 comments